{"id":774,"date":"2023-12-22T08:11:15","date_gmt":"2023-12-22T08:11:15","guid":{"rendered":"https:\/\/greymatterpharma.com\/?page_id=774"},"modified":"2026-04-28T09:42:59","modified_gmt":"2026-04-28T08:42:59","slug":"reserached-pipelines","status":"publish","type":"page","link":"https:\/\/greymatterpharma.com\/index.php\/reserached-pipelines\/","title":{"rendered":"Reserached Pipelines"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Pipeline: Highlighting the Promising Drugs in Development\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\n \"\"\n \n \n \n <\/div>\n
\n
\n

GM28K - Treatment resistant depression (TRD):<\/h2> <\/div>\n

A novel approach to treating Treatment-Resistant Depression (TRD), aiming to improve lives and reduce dependency. GM28K represents a groundbreaking advancement in addressing TRD, offering new hope for those struggling with this challenging condition.<\/p><\/div><\/div><\/div><\/div>

\u00a0<\/div>
\u00a0<\/div><\/div><\/div><\/div><\/section>
\u00a0<\/div><\/div> <\/div>\n <\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\n \"\"\n \n \n \n <\/div>\n
\n
\n

GRE2811 - Treatment Of Alopecia<\/h2> <\/div>\n

Targeting Alopecia with groundbreaking pharmaceutical therapy. GRE2811 stands at the forefront of our efforts to address hair loss, offering a new dimension in the treatment landscape for individuals grappling with Alopecia.<\/p><\/div> <\/div>\n <\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\n \"\"\n \n \n \n <\/div>\n
\n
\n

GM2813 - Gambling Disorder<\/h2> <\/div>\n

Innovative solutions for combating Gambling Disorder. GM2813 represents a dedicated initiative to address the complexities of Gambling Disorder, offering a ray of hope for those entangled in the grip of compulsive gambling.<\/p><\/div> <\/div>\n <\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\n \"\"\n \n \n \n <\/div>\n
\n
\n

GM2814 - Mild Cognitive Impairment (MCI)<\/h2> <\/div>\n

Addressing Mild Cognitive Impairment with advanced drug repurposing strategies. GM2814 symbolizes our commitment to enhancing cognitive health and function. By employing cutting-edge drug repurposing techniques,<\/p><\/div> <\/div>\n <\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Our Innovative Research Pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Our innovative research pipeline underscores our dedication to pioneering pharmaceutical solutions that make a difference in the lives of individuals facing various challenges. Through these promising drug developments, we aim to contribute to a healthier, more resilient future.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Our Pipeline: Highlighting the Promising Drugs in Development GM28K – Treatment resistant depression (TRD): A novel approach to treating Treatment-Resistant Depression (TRD), aiming to improve lives and reduce dependency. GM28K represents a groundbreaking advancement in addressing TRD, offering new hope for those struggling with this challenging condition. \u00a0\u00a0 \u00a0 GRE2811 – Treatment Of Alopecia Targeting Alopecia with groundbreaking pharmaceutical therapy….<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-774","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/pages\/774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/comments?post=774"}],"version-history":[{"count":22,"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/pages\/774\/revisions"}],"predecessor-version":[{"id":965,"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/pages\/774\/revisions\/965"}],"wp:attachment":[{"href":"https:\/\/greymatterpharma.com\/index.php\/wp-json\/wp\/v2\/media?parent=774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}